Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision |
hepatocellular_carcinoma [2019/09/10 19:56] – [Current clinical risk assessment] admin | hepatocellular_carcinoma [2019/09/12 17:14] – [Related work] admin |
---|
| |
==== Publication: ==== | ==== Publication: ==== |
Jessica Zavadil, Maryanne Herzig, Kim Hildreth, Amir Foroushani, William Boswell, Ronald Walter, Robert Reddick, Hugh White, Habil Zare. C3HeB/FeJ Mice Mimic Gene Expression and Pathobiological Features of Human Hepatocellular Carcinoma, //Molecular Carcinogenesis//, In press. | |
{{:wiki:public:jessica_compare.png?direct&400|}} | Jessica Zavadil, Maryanne Herzig, Kim Hildreth, Amir Foroushani, William Boswell, Ronald Walter, Robert Reddick, Hugh White, Habil Zare. "C3HeB/FeJ Mice mimic many aspects of gene expression and pathobiological features of human hepatocellular carcinoma." [[https://onlinelibrary.wiley.com/doi/abs/10.1002/mc.22929|Molecular carcinogenesis ]]58.3 (2019): 309-320. |
| |
| {{:wiki:public:jessica_compare.png?direct&400}} |
| |
==== Project 2: ==== | ==== Project 2: ==== |
| |
- Hart, Steven N., et al. "Calculating sample size estimates for RNA sequencing data." //Journal of Computational [[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842884/|Biology]]//20.12 (2013): 970-978.Wu, Hao, Chi Wang, and Zhijin Wu. "PROPER: comprehensive power evaluation for differential expression using RNA-seq." //[[http://bioinformatics.oxfordjournals.org/content/31/2/233.short|Bioinformatics]]//31.2 (2015): 233-241.From [[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842884/figure/f2/|Fig2]] and [[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842884/figure/f2/|Fig3]] of Huang et al. paper, and [[http://bioinformatics.oxfordjournals.org.libproxy.txstate.edu/content/31/2/233/F5.expansion.html|Fig5]] of Hart et al., it seems that at least 5-7 samples are needed for each condition. | - Hart, Steven N., et al. "Calculating sample size estimates for RNA sequencing data." //Journal of Computational [[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842884/|Biology]]//20.12 (2013): 970-978.Wu, Hao, Chi Wang, and Zhijin Wu. "PROPER: comprehensive power evaluation for differential expression using RNA-seq." //[[http://bioinformatics.oxfordjournals.org/content/31/2/233.short|Bioinformatics]]//31.2 (2015): 233-241.From [[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842884/figure/f2/|Fig2]] and [[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842884/figure/f2/|Fig3]] of Huang et al. paper, and [[http://bioinformatics.oxfordjournals.org.libproxy.txstate.edu/content/31/2/233/F5.expansion.html|Fig5]] of Hart et al., it seems that at least 5-7 samples are needed for each condition. |
- Ching, Travers, Sijia Huang, and Lana X. Garmire. "Power analysis and sample size estimation for RNA-Seq differential expression." //[[http://rnajournal.cshlp.org/content/early/2014/09/22/rna.046011.114|rna]]//20.11 (2014): 1684-1696. | - Ching, Travers, Sijia Huang, and Lana X. Garmire. "Power analysis and sample size estimation for RNA-Seq differential expression." //[[http://rnajournal.cshlp.org/content/early/2014/09/22/rna.046011.114|rna]]//20.11 (2014): 1684-1696. |
- Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma, [[http://www.cell.com/cell/abstract/S0092-8674(17)30639-6?innerTabgraphical_S0092867417306396|Cell]], 2017 [{{:ally-copmprehensive_and_integrative_genomic_char_of_hcc-cell-2017.pdf|pdf}} ]. TCGA's HCC data and subtyping using DNA copy number, DNA methylation, mRNA expression, miRNA expression and RPPA (protein expression). Links to the MDACC dataset with 100 HCC samples. | - Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma, [[http://www.cell.com/cell/abstract/S0092-8674(17)30639-6?innerTabgraphical_S0092867417306396|Cell]], 2017 [{{:ally-copmprehensive_and_integrative_genomic_char_of_hcc-cell-2017.pdf|pdf}} ]. TCGA's HCC data and subtyping using DNA copy number, DNA methylation, mRNA expression, miRNA expression and RPPA (protein expression). Links to the MDACC dataset with 100 HCC samples. |
| - Subramaniam, Somasundaram, Robin K. Kelley, and Alan P. Venook. "A review of hepatocellular carcinoma (HCC) staging systems." [[http://cco.amegroups.com/article/view/2528/3943|Chinese clinical oncology]] 2.4 (2013). |
---- | |
| |
===== Current clinical risk assessment ===== | |
| |
Percent rise in AFP and the total amount of AFP (alpha feto protein) is a common risk indicator for HCC. If it rises quickly it suggests aggressive tumor. If AFP is over 500 it suggests vascular involvement or aggressiveness. If regionally ablated and recurs within three months, this is also suggestive of an aggressive tumor. Other criteria include: disease burden, CP cirrhosis, portal vein thrombosis, AFP. CLIP score and BCLC score are also used in clinic. | |
| |
---- | ---- |